Emerging data suggest this peptide, a dual agonist targeting both incretin and another hormone, appears to provide a notable step forward for body treatment. Initial human trials have demonstrated substantial reductions in abdominal fat , possibly outperforming current obesity medications . However , additional assessment is needed to completely de